NMR screening methods for drug discovery

Advances in Biomedical Spectroscopy

Volumn 3, Issue , 2011, Pages 381-412

  Shortridge, Matthew D ^a   Powers, Robert ^a  

^a UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

Drug discovery; functional annotation; library design; NMR ligand affinity screens; rapid co structures

Indexed keywords

EID: 84865470647     PISSN: 18750656     EISSN: None     Source Type: Book Series    
DOI: 10.3233/978-1-60750-695-9-381     Document Type: Article

References (232)

1. F. Sams-Dodd, Drug discovery: selecting the optimal approach, Drug Discov. Today 11(2006), 465-472.
2. G. C. Terstappen, C. Schluepen, R. Raggiaschi, G. Gaviraghi, Target deconvolution strategies in drug discovery, Nat. Rev. Drug Discovery 6(2007), 891-903.
3. J. P. E. Karlberg, Trends in disease focus of drug development, Nat. Rev. Drug Discovery 7(2008), 639-640.
4. A. C. Anderson, The Process of Structure-Based Drug Design Chem. Biol. 10(2003), 787-797.
5. G. M. Lee, C. S. Craik, Trapping Moving Targets with Small Molecules, Science 324(2009), 213-215.
6. O. Keskin, A. Gursoy, B. Ma, R. Nussinov, Towards drugs targeting multiple proteins in a systems biology approach. Curr. Top. Med. Chem. (Sharjah, United Arab Emirates) 7(2007), 943-951.
7. J. W. Armstrong, A review of high-throughput screening approaches for drug discovery, Am. Biotechnol. Lab. 17(1999), 26-28.
8. J. E. Gonzalez, P. A. Negulescu, Intracellular detection assays for high-throughput screening, Curr. Opin. Biotechnol. 9(1998), 624-631.
9. K. R. Oldenburg, Current and future trends in high throughput screening for drug discovery, Annu. Rep. Med. Chem 33(1998), 301-311.
10. P. B. Fernandes, Technological advances in high-throughput screening, Curr. Opin. Chem. Biol. 2(1998), 597-603.
11. B. A. Kenny, M. Bushfield, D. J. Parry-Smith, S. Fogarty, J. M. Treherne, The application of highthroughput screening to novel lead discovery, Prog. Drug Res. 51(1998), 245-269.
12. J. T. Koh, Making virtual screening a reality, Proc. Natl. Acad. Sci. U. S. A. 100(2003), 6902-6903.
13. S. S. Phatak, C. C. Stephan, C. N. Cavasotto, High-throughput and in silico screenings in drug discovery, Expert Opin. Drug Discovery 4(2009), 947-959.
14. M. J. McGregor, Z. Luo, X. Jiang, Virtual screening in drug discovery, Drug Discovery Res. (2007), 63-88, 2 plates.
15. G. M. Rishton, Reactive compounds and in vitro false positives in HTS, Drug Discov. Today 2(1997), 382-384.
16. S. L. McGovern, E. Caselli, N. Grigorieff, B. K Shoichet, A Common Mechanism Underlying Promiscuous Inhibitors from Virtual and High-Throughput Screening, J. Med. Chem. 45(2002), 1712-1722.
17. S. L. McGovern, B. T. Helfand, B. Feng, B. K. Shoichet, A Specific Mechanism of Nonspecific Inhibition, J. Med. Chem. 46(2003), 4265-4272.
18. J. Seidler, S. L. McGovern, T. N. Doman, B. K. Shoichet, Identification and Prediction of Promiscuous Aggregating Inhibitors among Known Drugs, J. Med. Chem. 46(2003), 4477-4486.
19. D. R. Goode, R. K Totten, J. T. Heeres, P. J. Hergenrother, Identification of Promiscuous Small Molecule Activators in High-Throughput Enzyme Activation Screens, J. Med. Chem. 51(2008), 2346-2349.
20. T. Polgar, A. Baki, G. I. Szendrei, G. M. Keseru, Comparative Virtual and Experimental High-Throughput Screening for Glycogen Synthase Kinase-3β Inhibitors, J. Med. Chem. 48(2005), 7946-7959.
21. T. N. Doman, S. L. McGovern, B. J. Witherbee, T. P. Kasten, R. Kurumbail, W. C. Stallings, D. T. Connolly, B. K Shoichet, Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B, J. Med. Chem. 45(2002), 2213-2221.
22. A. M. Paiva, D. E. Vanderwall, J. S. Blanchard, J. W. Kozarich, J. M. Williamson, T. M. Kelly, Inhibitors of dihydrodipicolinate reductase, a key enzyme of the diaminopimelate pathway of Mycobacterium tuberculosis, Biochim. Biophys. Acta 1545(2001), 67-77.
23. A. Dove, A. Marshall, Drug screening-beyond the bottleneck. Nat. Biotechnol. 17(1999), 859-863.
24. J. Stark, R. Powers, Rapid protein-ligand costructures using chemical shift perturbations, J. Am. Chem. Soc. 130(2008), 535-545.
25. M. Pellecchia, I. Bertini, D. Cowburn, C. Dalvit, E. Giralt, W. Jahnke, T. L. James, S. W. Homans, H. Kessler, C. Luchinat, B. Meyer, H. Oschkinat, J. Peng, H. Schwalbe, G Siegal, Perspectives on NMR in drug discovery: a technique comes of age, Nat. Rev. Drug Discov. 7(2008), 738-745.
26. R. Powers, Advances in nuclear magnetic resonance for drug discovery, Expert Opin. Drug Discovery 4(2009), 1077-1098.
27. K. A. Mercier, M. Baran, V. Ramanathan, P. Revesz, R. Xiao, G. T. Montelione, R. Powers, FAST-NMR: functional annotation screening technology using NMR spectroscopy, J. Am. Chem. Soc. 128(2006), 15292-15299.
28. R. Powers, K. A. Mercier, J. C. Copeland, The application of FAST-NMR for the identification of novel drug discovery targets, Drug Discov. Today 13(2008), 172-179.
29. M. D. Shortridge, D. S. Hage, G. S. Harbison, R. Powers, Estimating protein-ligand binding affinity using high-throughput screening by NMR, J. Comb. Chem. 10(2008), 948-958.
30. P. J. Hajduk, J. Greer, A decade of fragment-based drug design: strategic advances and lessons learned, Nat. Rev. Drug Discovery 6(2007), 211-219.
31. G Liu, Y. Shen, H. S. Atreya, D. Parish, Y. Shao, D. K Sukumaran, R. Xiao, A. Yee, A. Lemak, A. Bhattacharya, T. A. Acton, C. H. Arrowsmith, G. T. Montelione, T. Szyperski, NMR data collection and analysis protocol for high-throughput protein structure determination, Proc. Natl. Acad. Sci. U. S. A. 102(2005), 10487-10492.
32. S. Tomaselli, L. Ragona, L. Zetta, M. Assfalg, P. Ferranti, R. Longhi, A. M. Bonvin, H. Molinari, NMR-based modeling and binding studies of a ternary complex between chicken liver bile acid binding protein and bile acids, Proteins 69(2007), 177-191.
33. R. Powers, NMR metabolomics and drug discovery, Magn. Reson. Chem. 47(2009), S2-S11.
34. D. Ekonomiuk, X. C. Su, K Ozawa, C. Bodenreider, S. P. Lim, Z. Yin, T. H. Keller, D. Beer, V. Patel, G Otting, A. Caflisch, D. Huang, Discovery of a non-peptidic inhibitor of west nile virus NS3 protease by high-throughput docking, PLoS Negl. Trop. Dis. 3(2009), e356.
35. J. Liu, D. Begley, D. D. Mitchell, C. L. Verlinde, G Varani, E. Fan, Multivalent drug design and inhibition of cholera toxin by specific and transient protein-ligand interactions, Chem. Biol. Drug Des. 71(2008), 408-419.
36. Z. Shi, S. Tabassum, W. Jiang, J. Zhang, S. Mathur, J. Wu, Y. Shi, Identification of a potent inhibitor of human dual-specific phosphatase, VHR, from computer-aided and NMR-based screening to cellular effects, ChemBioChem 8(2007), 2092-2099.
37. U. Rothweiler, A. Czarna, M. Krajewski, J. Ciombor, C. Kalinski, V. Khazak, G Ross, N. Skobeleva, L. Weber, T. A. Holak, Isoquinolin-1-one inhibitors of the MDM2-p53 interaction, ChemMedChem 3(2008), 1118-1128.
38. D. H. Tsao, A. G. Sutherland, L. D. Jennings, Y. Li, T. S. Rush, 3rd, J. C. Alvarez, W. Ding, E. G. Dushin, R. G. Dushin, S. A. Haney, C. H. Kenny, A. K. Malakian, R. Nilakantan, L. Mosyak, Discovery of novel inhibitors of the ZipA/FtsZ complex by NMR fragment screening coupled with structure-based design, Bioorg. Med. Chem. 14(2006), 7953-7961.
39. D. Grandy, J. Shan, X. Zhang, S. Rao, S. Akunuru, H. Li, Y. Zhang, I. Alpatov, X. A. Zhang, R. A. Lang, D. L. Shi, J. J. Zheng, Discovery and characterization of a small molecule inhibitor of the PDZ domain of dishevelled, J. Biol. Chem. 284(2009), 16256-16263.
40. M. Brewer, O. Ichihara, C. Kirchhoff, M. Schade, M. Whittaker, Assembling a Fragment Library, in Fragment-Based Drug Discovery, M. J. S. Edward R. Zartler, Editor. 2008, John Wiley & Sons, Ltd: Hoboken, NJ 39-62.
41. A. L. Hopkins, C. R. Groom, A. Alex, Ligand efficiency: a useful metric for lead selection, Drug Discov. Today 9(2004), 430-431.
42. A. Schuffenhauer, S. Ruedisser, A. L. Marzinzik, W. Jahnke, M. Blommers, P. Selzer, E. Jacoby, Library design for fragment based screening, Curr. Top. Med. Chem. (Sharjah, United Arab Emirates) 5(2005), 751-762.
43. T. Fink, H. Bruggesser, J.-L. Reymond, Virtual exploration of the small-molecule chemical universe below 160 D, Angew. Chem. Int. Ed. 44(2005), 1504-1508.
44. P. J. Hajduk, SAR by NMR: putting the pieces together, Mol. Interventions 6(2006), 266-272.
45. A. Smith, Screening for drug discovery: the leading question, Nature 418(2002), 453-459.
46. J. Drews, Drug discovery: A historical perspective, Science 287(2000), 1960-1963.
47. J. Bajorath, Rational drug discovery revisited: interfacing experimental programs with bio-and chemoinformatics, Drug Discov. Today 6(2001), 989-995.
48. R. Lahana, How many leads from HTS?, Drug Discov. Today 4(1999), 447-448.
49. J. Fejzo, C. A. Lepre, J. W. Peng, G. W. Bemis, Ajay, M. A. Murcko, J. M. Moore, The SHAPES strategy: and NMR-based approach for lead generation in drug discovery, Chem. Biol. 6(1999), 755-769.
50. P. J. Hajduk, E. T. Olejniczak, S. W. Fesik, One-Dimensional Relaxation-and Diffusion-Edited NMR Methods for Screening Compounds That Bind to Macromolecules, J. Am. Chem. Soc. 119(1997), 12257-12261.
51. S. B. Shuker, P. J. Hajduk, R. P. Meadow, S. W. Feisk, Discovering High-Affinity Ligands for Proteins: SAR by NMR, Science 274(1996), 1531-1534.
52. G. Wagner, S. G. Hyberts, T. F. Havel, NMR Structure Determination in Solution: A Critique and Comparison with X-Ray Crystallography, Annu. Rev. Biophys. Biomol. Struct 21(1992), 167-198.
53. S. Vanwetswinkel, R. J. Heetebrij, J.v. Duynhoven, J. G. Hollander, D. V. Filippov, P. Hajduk, G. Siegal, TINS, Target Immobilized NMR Screening, Chem. Biol. 12(2005), 207-216.
54. J. W. Peng, J. Moore, N. Abdul-Manan, NMR experiments for lead generation in drug discovery, Prog. Nucl. Magn. Reson. Spectrosc. 44(2004), 225-256.
55. S. B. Shuker, P. J. Hajduk, R. P. Meadows, S. W. Fesik, Discovering high-affinity ligands for proteins: SAR by NMR, Science 274(1996), 1531-1534.
56. E. R. Zartler, J. Hanson, B. E. Jones, A. D. Kline, G. Martin, H. Mo, M. J. Shapiro, R. Wang, H. Wu, J. Yan, RAMPED-UP NMR: multiplexed NMR-based screening for drug discovery, J. Am. Chem. Soc. 125(2003), 10941-10946.
57. M. Mayer, B. Meyer, Characterization of ligand binding by saturation transfer difference NMR spectroscopy, Angew. Chem. Int. Ed. 38(1999), 1784-1788.
58. D. S. Sem, B. Bertolaet, B. Baker, E. Chang, A. D. Costache, S. Coutts, Q. Dong, M. Hansen, V. Hong, X. Huang, R. M. Jack, R. Kho, H. Lang, C.-T. Ma, D. Meininger, M. Pellecchia, F. Pierre, H. Villar, L. Yu, Systems-Based Design of Bi-Ligand Inhibitors of Oxidoreductases Filling the Chemical Proteomic Toolbox, Chem. Biol. 11(2004), 185-194.
59. C. Dalvit, P. Pevarello, M. Tato, M. Veronesi, A. Vulpetti, M. Sundstrom, Identification of compounds with binding affinity to proteins via magnetization transfer from bulk water, J. Biomol. NMR 18(2000), 65-68.
60. M. Bista, K. Kowalska, W. Janczyk, A. Doemling, T. A. Holak, Robust NMR Screening for Lead Compounds Using Tryptophan-Containing Proteins, J. Am. Chem. Soc. 131(2009), 7500-7501.
61. L. D'Silva, P. Ozdowy, M. Krajewski, U. Rothweiler, M. Singh, T. A. Holak, Monitoring the Effects of Antagonists on Protein-Protein Interactions with NMR Spectroscopy, J. Am. Chem. Soc. 127(2005), 13220-13226.
62. C. Dalvit, P. E. Fagerness, D. T. A. Hadden, R. W. Sarver, B. J. Stockman, Fluorine-NMR experiments for high-throughput screening: Theoretical aspects, practical considerations, and range of applicability, J. Am. Chem. Soc. 125(2003), 7696-7703.
63. W. Jahnke, S. Ruedisser, M. Zurini, Spin label enhanced NMR screening, J. Am. Chem. Soc. 123(2001), 3149-3150.
64. M. Lin, M. J. Shapiro, J. R. Wareing, Diffusion-Edited NMR-Affinity NMR for Direct Observation of Molecular Interactions, J. Am. Chem. Soc. 119(1997), 5249-5250.
65. C. Dalvit, E. Ardini, G. P. Fogliatto, N. Mongelli, M. Veronesi, Reliable high-throughput functional screening with 3-FABS, Drug Discov. Today 9(2004), 595-602.
66. A. Chen, M. J. Shapiro, NOE Pumping: A Novel NMR Technique for Identification of Compounds with Binding Affinity to Macromolecules, J. Am. Chem. Soc. 120(1998), 10258-10259.
67. K. A. Mercier, M. D. Shortridge, R. Powers, A multi-step NMR screen for the identification and evaluation of chemical leads for drug discovery, Comb. Chem. High Throughput Screen 12(2009), 285-295.
68. F. J. Moy, K. Haraki, D. Mobilio, G. Walker, R. Powers, K. Tabei, H. Tong, M. M. Siegel, MS/NMR: a structure-based approach for discovering protein ligands and for drug design by coupling size exclusion chromatography, mass spectrometry, and nuclear magnetic resonance spectroscopy, Anal. Chem. 73(2001), 571-581.
69. V. M. Sanchez-Pedregal, M. Reese, J. Meiler, M. J. J. Blommers, C. Griesinger, T. Carlomagno, The INPHARMA method: Protein-mediated interligand NOEs for pharmacophore mapping, Angew. Chem. Int. Ed. 44(2005), 4172-4175.
70. C. Ludwig, P. J. A. Michiels, X. Wu, K. L. Kavanagh, E. Pilka, A. Jansson, U. Oppermann, U. L. Guenther, SALMON: Solvent Accessibility, Ligand binding, and Mapping of ligand Orientation by NMR Spectroscopy, J. Med. Chem. 51(2008), 1-3.
71. J. Xie, R. Thapa, S. Reverdatto, D. S. Burz, A. Shekhtman, Screening of small molecule interactor library by using in-cell NMR spectroscopy (SMILI-NMR), J. Med. Chem. 52(2009), 3516-3522.
72. D. S. Burz, K. Dutta, D. Cowburn, A. Shekhtman, In-cell NMR for protein-protein interactions (STINT-NMR), Nat. Protoc. 1(2006), 146-152.
73. D. S. Burz, K. Dutta, D. Cowburn, A. Shekhtman, Mapping structural interactions using in-cell NMR spectroscopy (STINT-NMR), Nat. Methods 3(2006), 91-93.
74. S. Vanwetswinkel, R. J. Heetebrij, J. van Duynhoven, J. G. Hollander, D. V. Filippov, P. J. Hajduk, G. Siegal, TINS, Target Immobilized NMR Screening: An Efficient and Sensitive Method for Ligand Discovery, Chem. Biol. 12(2005), 207-216.
75. R. S. Bohacek, C. McMartin, W. C. Guida, The art and practice of structure-based drug design: a molecular modeling perspective, Med. Res. Rev. 16(1996), 3-50.
76. O. Koji, I. Tetsu, Y. Hiroshi, K. Hideo, A Quantitative Approach to the Estimation of Chemical Space from a Given Geometry by the Combination of Atomic Species, QSAR Comb. Sci. 26(2007), 596-607.
77. R. S. Bohacek, C. McMartin, W. C. Guida, The art and practice of structure-based drug design: a molecular modeling perspective, Med. Res. Rev. 16(1996), 3-50.
78. M. H. J. Seifert, Targeted scoring functions for virtual screening, Drug Discov. Today 14(2009), 562-569.
79. J. Xu, J. Stevenson, Drug-like Index: A New Approach To Measure Drug-like Compounds and Their Diversity, J. Chem. Inf. Comput. Sci. 40(2000), 1177-1187.
80. L. Xue, J. Bajorath, Molecular descriptors in chemoinformatics, computational combinatorial chemistry, and virtual screening, Comb. Chem. High Throughput Screening 3(2000), 363-372.
81. R. A. Lewis, S. D. Pickett, D. E. Clark, Computer-aided molecular diversity analysis and combinatorial library design, Rev. Comput. Chem 16(2000), 1-51.
82. P. Willett, Chemoinformatics - similarity and diversity in chemical libraries, Curr. Opin. Biotechnol. 11(2000), 85-88.
83. D. C. Spellmeyer, P. D. J. Grootenhuis, Recent developments in molecular diversity. Computational approaches to combinatorial chemistry, Annu. Rep. Med. Chem 34(1999), 287-296.
84. D. Gorse, R. Lahana, Functional diversity of compound libraries, Curr. Opin. Chem. Biol. 4(2000), 287-294.
85. P. D. Leeson, B. Springthorpe, The influence of drug-like concepts on decision-making in medicinal chemistry, Nat. Rev. Drug Discovery 6(2007), 881-890.
86. C. A. Lipinski, F. Lombardo, B. W. Dominy, P. J. Feeney, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Adv. Drug Delivery Rev. 46(2001), 3-26.
87. C. A. Lipinski, Lead-and drug-like compounds: the rule-of-five revolution, Drug Discov. Today Technol. 1(2004), 337-341.
88. C. A. Lepre, Library design for NMR-based screening, Drug Discov. Today 6(2001), 133-140.
89. K. A. Mercier, R. Powers, Determining the optimal size of small molecule mixtures for high throughput NMR screening, J. Biomol. NMR 31(2005), 243-58.
90. D. A. Erlanson, Fragment-based lead discovery: A chemical update, Curr. Opin. Biotechnol. 17(2006), 643-652.
91. M. Fischer, R. E. Hubbard, Fragment-based ligand discovery. Mol. Interventions 9(2009), 22-30.
92. M. Congreve, C. W. Murray, R. Carr, D. C. Rees, Fragment-based lead discovery, Annu. Rep. Med. Chem. 42(2007), 431-448.
93. G. Siegal, E. Ab, J. Schultz, Integration of fragment screening and library design, Drug Discov. Today 12(2007), 1032-1039.
94. I. V. Tetko, J. Gasteiger, R. Todeschini, A. Mauri, D. Livingstone, P. Ertl, V. A. Palyulin, E. V. Radchenko, N. S. Zefirov, A. S. Makarenko, V. Y. Tanchuk, V. V. Prokopenko, Virtual computational chemistry laboratory - design and description, J. Comput.-Aided Mol. Des. 19(2005), 453-463.
95. O. Ivanciuc, A. T. Balaban, The graph description of chemical structures. in Topological Indices and Related Descriptors in QSAR and QSPR, J. Devillers and A. T. Balaban, Editors. 1999, Gordon and Breach Science Publishers, The Netherlands, 59-167.
96. Y. S. Prabhakar, M. K. Gupta, Chemical structure indices in in silico molecular design, Sci. Pharm. 76(2008), 101-132.
97. A. T. Balaban, D. Ciubotariu, M. Medeleanu, Topological indices and real number vertex invariants based on graph eigenvalues or eigenvectors, J. Chem. Inf. Comput. Sci. 31(1991), 517-523.
98. J. Auer, J. Bajorath, Molecular similarity concepts and search calculations, Methods Mol. Biol. 453(2008), 327-347.
99. P. Willett, Searching techniques for databases of two-and three-dimensional chemical structures, J. Med. Chem. 48(2005), 4183-4199.
100. D. E. Patterson, R. D. Cramer, A. M. Ferguson, R. D. Clark, L. E. Weinberger, Neighborhood behavior: a useful concept for validation of "molecular diversity" descriptors, J. Med. Chem. 39(1996), 3049-3059.
101. E. Lasser Karen, D. Allen Paul, J. Woolhandler Steffie, U. Himmelstein David, M. Wolfe Sidney, H. Bor David, Timing of new black box warnings and withdrawals for prescription medications, JAMA 287(2002), 2215-2220.
102. J. A. Kramer, J. E. Sagartz, D. L. Morris, The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates, Nat. Rev. Drug Discovery 6(2007), 636-649.
103. C. W. Andrews, L. Bennett, L. X. Yu, Predicting human oral bioavailability of a compound: development of a novel quantitative structure-bioavailability relationship, Pharm. Res. 17(2000), 639-644.
104. D. E. Clark, S. D. Pickett, Computational methods for the prediction of 'drug-likeness', Drug Discov. Today 5(2000), 49-58.
105. J. C. Adams, M. J. Keiser, L. Basuino, H. F. Chambers, D. S. Lee, O. G. Wiest, P. C. Babbitt, A mapping of drug space from the viewpoint of small molecule metabolism, PLoS Comput. Biol. 5(2009), e1000474.
106. H. Mishra, N. Singh, T. Lahiri, K. Misra, A comparative study on the molecular descriptors for predicting drug-likeness of small molecules, Bioinformation 3(2009), 384-388.
107. G. M. Rishton, Reactive compounds and in vitro false positives in HTS, Drug Discov. Today 2(1997), 382-384.
108. G. Chessari, A. J. Woodhead, From fragment to clinical candidate - a historical perspective, Drug Discov. Today 14(2009), 668-675.
109. K. Eitner, U. Koch, From fragment screening to potent binders: strategies for fragment-to-lead evolution, Mini Rev. Med. Chem. 9(2009), 956-961.
110. M. Pellecchia, Fragment-based drug discovery takes a virtual turn, Nat. Chem. Biol. 5(2009), 274-275.
111. M. F. Schmidt, J. Rademann, Dynamic template-assisted strategies in fragment-based drug discovery, Trends Biotechnol. 27(2009), 512-521.
112. K. A. Mercier, K. Germer, R. Powers, Design and characterization of a functional library for NMR screening against novel protein targets, Comb. Chem. High Throughput Screen 9(2006), 515-534.
113. A. Dove, Drug screening-beyond the bottleneck, Nat. Biotechnol. 17(1999), 859-863.
114. C. A. Lepre, J. Peng, J. Fejzo, N. Abdul-Manan, J. Pocas, M. Jacobs, X. Xie, J. M. Moore, Applications of SHAPES screening in drug discovery, Comb. Chem. High Throughput Screen 5(2002), 583-590.
115. H. Widmer, W. Jahnke, Protein NMR in biomedical research. Cell Mol. Life Sci. 61(2004), 580-599.
116. O. Jardetzky, N. G. Wade-Jardetzky, On the mechanism of the binding of sulfonamides to bovine serum albumin, Mol. Pharmacol. 1(1965), 214-230.
117. J. J. Fischer, O. Jardetzky, Nuclear Magnetic Relaxation Study of Intermolecular Complexes. The Mechanism of Penicillin Binding to Serum Albumin, J. Am. Chem. Soc. 87(1965), 3237-3244.
118. M. J. van Dongen, J. Uppenberg, S. Svensson, T. Lundback, T. Akerud, M. Wikstrom, J. Schultz, Structure-based screening as applied to human FABP4: a highly efficient alternative to HTS for hit generation, J. Am. Chem. Soc. 124(2002), 11874-11880.
119. R. T. McKay, A. W. Graham, Chapter 2 Recent Advances in Solvent Suppression for Solution NMR: A Practical Reference, in Annual Reports on NMR Spectroscopy. 2009, Academic Press, 33-76.
120. D. Shao, T. J. Berrodin, E. Manas, D. Hauze, R. Powers, A. Bapat, D. Gonder, R. C. Winneker, D. E. Frail, Identification of novel estrogen receptor a antagonists, J. Steroid. Biochem. Mol. Biol. 88(2004), 351-360.
121. H. Qin, J. Shi, R. Noberini, E. B. Pasquale, J. Song, Crystal Structure and NMR Binding Reveal That Two Small Molecule Antagonists Target the High Affinity Ephrin-binding Channel of the EphA4 Receptor, J. Biol. Chem. 283(2008), 29473-29484.
122. L. Poppe, T. S. Harvey, C. Mohr, J. Zondlo, C. M. Tegley, O. Nuanmanee, J. Cheetham, Discovery of ligands for Nurr1 by combined use of NMR screening with different isotopic and spin-labeling strategies, J. Biomol. Screening 12(2007), 301-311.
123. A.-S. Bretonnet, A. Jochum, O. Walker, I. Krimm, P. Goekjian, O. Marcillat, J.-M. Lancelin, NMR Screening Applied to the Fragment-Based Generation of Inhibitors of Creatine Kinase Exploiting a New Interaction Proximate to the ATP Binding Site, J. Med. Chem. 50(2007), 1865-1875.
124. M. Piazza, L. Yu, A. Teghanemt, T. Gioannini, J. Weiss, F. Peri, Evidence of a Specific Interaction between New Synthetic Antisepsis Agents and CD14, Biochemistry 48(2009), 12337-12344.
125. K. Jaudzems, J. Kuka, A. Gutsaits, K. Zinovjevs, I. Kalvinsh, E. Liepinsh, E. Liepinsh, M. Dambrova, Inhibition of carnitine acetyltransferase by mildronate, a regulator of energy metabolism, J. Enzyme Inhib. Med. Chem. 24(2009), 1269-1275.
126. J.-Y. Lee, K-W. Jeong, J.-U. Lee, D.-I. Kang, Y. Kim, Novel E. coli P-ketoacyl-acyl carrier protein synthase III inhibitors as targeted antibiotics, Bioorg. Med. Chem. 17(2009), 1506-1513.
127. M. Simcic, M. Hodoscek, J. Humljan, K. Kristan, U. Urleb, D. Kocjan, S. G Grdadolnik, NMR and Molecular Dynamics Study of the Binding Mode of Naphthalene-N-sulfonyl-D-glutamic Acid Derivatives: Novel MurD Ligase Inhibitors, J. Med. Chem. 52(2009), 2899-2908.
128. A. Blume, M. Fitzen, A. J. Benie, T. Peters, Specificity of ligand binding to yeast hexokinase PII studied by STD-NMR, Carbohydr. Res. 344(2009), 1567-1574.
129. J.-C. Westermann, R. J. Clark, D. J. Craik, Binding mode of a-conotoxins to an acetylcholine binding protein determined by saturation transfer difference NMR, Protein Pept. Lett. 15(2008), 910-914.
130. M. G Szczepina, R. B. Zheng, G. C. Completo, T. L. Lowary, B. M. Pinto, STD-NMR Studies Suggest that Two Acceptor Substrates for GlfT2, a Bifunctional Galactofuranosyltransferase Required for the Biosynthesis of Mycobacterium tuberculosis Arabinogalactan, Compete for the Same Binding Site, ChemBioChem 10(2009), 2052-2059.
131. V. V. Krishnan, Ligand screening by saturation-transfer difference (STD) NMR spectroscopy, Curr. Anal. Chem. 1(2005), 307-320.
132. G Zhu, X. Yao, TROSY-based NMR experiments for NMR studies of large biomolecules, Prog. Nucl. Magn. Reson. Spectrosc. 52(2008), 49-68.
133. S. Mori, C. Abeygunawardana, M. O. N. Johnson, P. C. M. van Zijl, Improved sensitivity of HSQC spectra of exchanging protons at short interscan delays using a new fast HSQC (FHSQC) detection scheme that avoids water saturation, J. Magn. Reson. Ser. B 108(1995), 94-98.
134. P. Schanda, E. Kupce, B. Brutscher, SOFAST-HMQC Experiments for Recording Two-dimensional Heteronuclear Correlation Spectra of Proteins within a Few Seconds, J. Biomol. NMR 33(2005), 199-211.
135. D. M. LeMaster, Deuterium labeling in NMR structural analysis of larger proteins, Q. Rev. Biophys. 23(1990), 133-174.
136. T. Kigawa, Y. Muto, S. Yokoyama, Cell-free synthesis and amino acid-selective stable isotope labeling of proteins for NMR analysis, J. Biomol. NMR 6(1995), 129-134.
137. N. K Goto, L. E. Kay, New developments in isotope labeling strategies for protein solution NMR spectroscopy, Curr. Opin. Struct. Biol. 10(2000), 585-592.
138. J. Fejzo, C. A. Lepre, J. W. Peng, G. W. Bemis, Ajay, M. A. Murcko, J. M. Moore, The SHAPES strategy: an NMR-based approach for lead generation in drug discovery, Chem. Biol. 6(1999), 755-769.
139. C. K. Wada, J. H. Holms, M. L. Curtin, Y. Dai, A. S. Florjancic, R. B. Garland, Y. Guo, H. R. Heyman, J. R. Stacey, D. H. Steinman, D. H. Albert, J. J. Bouska, I. N. Elmore, C. L. Goodfellow, P. A. Marcotte, P. Tapang, D. W. Morgan, M. R. Michaelides, S. K. Davidsen, Phenoxyphenyl Sulfone N-Formylhydroxylamines (Retrohydroxamates) as Potent, Selective, Orally Bioavailable Matrix Metalloproteinase Inhibitors, J. Med. Chem. 45(2002), 219-232.
140. M. N. Schulz, R. E. Hubbard, Recent progress in fragment-based lead discovery, Curr. Opin. Pharmacol. 9(2009), 615-621.
141. T. J. Mitchison, Towards a pharmacological genetics, Chem. Biol. 1(1994), 3-6.
142. B. R. Stockwell, S. J. Haggarty, S. L. Schreiber, High-throughput screening of small molecules in miniaturized mammalian cell-based assays involving post-translational modifications, Chem. Biol. 6(1999), 71-83.
143. C. M. Crews, U. Splittgerber, Chemical genetics: exploring and controlling cellular processes with chemical probes, Trends Biochem. Sci. 24(1999), 317-320.
144. L. Burdine, T. Kodadek, Target identification in chemical genetics: the (often) missing link, Chem. Biol. 11(2004), 593-597.
145. T. U. Mayer, T. M. Kapoor, S. J. Haggarty, R. W. King, S. L. Schreiber, T. J. Mitchison, Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen, Science 286(1999), 971-974.
146. J. R. Peterson, R. S. Lokey, T. J. Mitchison, M. W. Kirschner, A chemical inhibitor of N-WASP reveals a new mechanism for targeting protein interactions, Proc. Natl. Acad. Sci. U. S. A. 98(2001), 10624-10629.
147. K. L. Carey, N. J. Westwood, T. J. Mitchison, G. E. Ward, A small-molecule approach to studying invasive mechanisms of Toxoplasma gondii, Proc. Natl. Acad. Sci. U. S. A. 101(2004), 7433-7438.
148. A. H. Julia, K. M. Lesley, W. K. Gavin, J. J. Joanna, P. F. Andrew, Nuclear magnetic resonance spectroscopy reveals the functional state of the signalling protein CheY in vivo in Escherichia coli, Mol. Microbiol. 49(2003), 1191-1200.
149. D. S. Burz, A. Shekhtman, Structural biology: Inside the living cell, Nature 458(2009), 37-38.
150. S. Reckel, R. Haensel, F. Loehr, V. Doetsch, In-cell NMR spectroscopy, Prog. Nucl. Magn. Reson. Spectrosc. 51(2007), 91-101.
151. T. Sakai, H. Tochio, T. Tenno, Y. Ito, T. Kokubo, H. Hiroaki, M. Shirakawa, In-cell NMR spectroscopy of proteins inside Xenopus laevis oocytes, J. Biomol. NMR 36(2006), 179-188.
152. S. Mari, D. Serrano-Gomez, F. J. Canada, A. L. Corbi, J. Jimenez-Barbero, 1D saturation transfer difference NMR experiments on living cells: the DC-SIGN/oligomannose interaction, Angew. Chem. Int. Ed. Engl. 44(2004), 296-298.
153. V. Doetsch, Investigation of proteins in living bacteria with in-cell NMR experiments, Top. Curr. Chem. 273(2008), 203-229.
154. S. Ogino, S. Kubo, R. Umemoto, S. Huang, N. Nishida, I. Shimada, Observation of NMR Signals from Proteins Introduced into Living Mammalian Cells by Reversible Membrane Permeabilization Using a Pore-Forming Toxin, Streptolysin O, J. Am. Chem. Soc. 131(2009), 10834-10835.
155. A. E. Ferentz, G. Wagner, NMR spectroscopy: a multifaceted approach to macromolecular structure, Q. Rev. Biophys. 33(2000), 29-65.
156. G. M. Clore, A. M. Gronenborn, Two-, three-, and four-dimensional NMR methods for obtaining larger and more precise three-dimensional structures of proteins in solution, Annu. Rev. Biophys. Biophys. Chem 20(1991), 29-63.
157. P. N. Reardon, L. D. Spicer, Multidimensional NMR spectroscopy for protein characterization and assignment inside cells, J. Am. Chem. Soc. 127(2005), 10848-10849.
158. Y. Shrot, L. Frydman, Single-scan NMR spectroscopy at arbitrary dimensions, J. Am. Chem. Soc. 125(2003), 11385-11396.
159. M. Gal, M. Mishkovsky, L. Frydman, Real-time monitoring of chemical transformations by ultrafast 2D NMR spectroscopy, J. Am. Chem. Soc. 128(2006), 951-956.
160. T. Szyperski, H. S. Atreya, Principles and applications of GFT projection NMR spectroscopy, Magn. Reson. Chem. 44 Spec No (2006), S51-S60.
161. H. S. Atreya, T. Szyperski, Rapid NMR data collection, Methods Enzymol. 394(2005), 78-108.
162. P. Schanda, V. Forge, B. Brutscher, HET-SOFAST NMR for fast detection of structural compactness and heterogeneity along polypeptide chains, Magn. Reson. Chem. 44 Spec No (2006), S177-S184.
163. P. Schanda, H. Van Melckebeke, B. Brutscher, Speeding up three-dimensional protein NMR experiments to a few minutes, J. Am. Chem. Soc. 128(2006), 9042-9043.
164. S. Hiller, F. Fiorito, K. Wuethrich, G. Wider, Automated projection spectroscopy (APSY), Proc. Natl. Acad. Sci. U. S. A. 102(2005), 10876-10881.
165. H. S. Atreya, T. Szyperski, G-matrix Fourier transform NMR spectroscopy for complete protein resonance assignment, Proc. Natl. Acad. Sci. U. S. A. 101(2004), 9642-9647.
166. H. R. Eghbalnia, A. Bahrami, M. Tonelli, K. Hallenga, J. L. Markley, High-Resolution Iterative Frequency Identification for NMR as a General Strategy for Multidimensional Data Collection, J. Am. Chem. Soc. 127(2005), 12528-12536.
167. B. E. Coggins, R. A. Venters, P. Zhou, Filtered Backprojection for the Reconstruction of a High-Resolution (4, 2) D CH3-NH NOESY Spectrum on a 29 kDa Protein, J. Am. Chem. Soc. 127(2005), 11562-11563.
168. D. K. Staykova, J. Fredriksson, W. Bermel, M. Billeter, Assignment of protein NMR spectra based on projections, multi-way decomposition and a fast correlation approach, J. Biomol. NMR 42(2008), 87-97.
169. T. Szyperski, D. C. Yeh, D. K. Sukumaran, H. N. B. Moseley, G. T. Montelione, Reduced-dimensionality NMR spectroscopy for high-throughput protein resonance assignment, Proc. Natl. Acad. Sci. U. S. A. 99(2002), 8009-8014.
170. D. S. Burz, K. Dutta, D. Cowburn, A. Shekhtman, In-cell NMR for protein-protein interactions (STINT-NMR), Nat. Protoc. 1(2006), 146-152.
171. D. S. Burz, K. Dutta, D. Cowburn, A. Shekhtman, Mapping structural interactions using in-cell NMR spectroscopy (STINT-NMR), Nat. Methods 3(2006), 91-93.
172. L. Fielding, NMR methods for the determination of protein-ligand dissociation constants, Prog. Nucl. Magn. Reson. Spectrosc. 51(2007), 219-242.
173. L. H. Lucas, C. K. Larive, Measuring ligand-protein binding using NMR diffusion experiments, Concepts Magn. Reson. Part A 20A (2004), 24-41.
174. Z. Ji, Z. Yao, M. Liu, Saturation transfer difference nuclear magnetic resonance study on the specific binding of ligand to protein, Anal. Biochem. 385(2009), 380-382.
175. K. A. Mercier, J. R. Cort, M. A. Kennedy, E. E. Lockert, S. Ni, M. D. Shortridge, R. Powers, Structure and function of Pseudomonas aeruginosa protein PA1324(21-170), Protein Sci 18(2009), 606-618.
176. S. D. Auweter, F. C. Oberstrass, F. H. T. Allain, Solving the Structure of PTB in Complex with Pyrimidine Tracts: An NMR Study of Protein-RNA Complexes of Weak Affinities, J. Mol. Biol. 367(2007), 174-186.
177. T. A. Pertinhez, E. Ferrari, E. Casali, J. A. Patel, A. Spisni, L. J. Smith, The binding cavity of mouse major urinary protein is optimised for a variety of ligand binding modes, Biochem. Biophys. Res. Commun. 390(2009), 1266-1271.
178. Y. Thielmann, J. Mohrlueder, B. W. Koenig, T. Stangler, R. Hartmann, K. Becker, H.-D. Hoeltje, D. Willbold, An indole-binding site is a major determinant of the ligand specificity of the GABA type A receptor-associated protein GABARAP, ChemBioChem 9(2008), 1767-1775.
179. M. Mayer, B. Meyer, Group Epitope Mapping by Saturation Transfer Difference NMR To Identify Segments of a Ligand in Direct Contact with a Protein Receptor, J. Am. Chem. Soc. 123(2001), 6108-6117.
180. C. Dalvit, M. Flocco, S. Knapp, M. Mostardini, R. Perego, B. J. Stockman, M. Veronesi, M. Varasi, High-throughput NMR-based screening with competition binding experiments, J. Am. Chem. Soc. 124(2002), 7702-7709.
181. W. Jahnke, P. Floersheim, C. Ostermeier, X. Zhang, R. Hemmig, K. Hurth, D. P. Uzunov, NMR reporter screening for the detection of high-affinity ligands, Angew. Chem. Int. Ed. 41(2002), 3420-3423.
182. C. Dalvit, M. Fasolini, M. Flocco, S. Knapp, P. Pevarello, M. Veronesi, NMR-Based Screening with Competition Water-Ligand Observed via Gradient Spectroscopy Experiments: Detection of High-Affinity Ligands, J. Med. Chem. 45(2002), 2610-2614.
183. A. H. Siriwardena, F. Tian, S. Noble, J. H. Prestegard, A straightforward NMR-spectroscopy-based method for rapid library screening, Angew. Chem. Int. Ed. 41(2002), 3454-3457.
184. C. Dalvit, M. Flocco, M. Veronesi, B. J. Stockman, Fluorine-NMR competition binding experiments for high-throughput screening of large compound mixtures, Comb. Chem. High Throughput Screening 5(2002), 605-611.
185. C. Dalvit, D. T. A. Hadden, R. W. Sarver, A. M. Ho, B. J. Stockman, Multi-selective one dimensional proton NMR experiments for rapid screening and binding affinity measurements, Comb. Chem. High Throughput Screening 6(2003), 445-453.
186. W. Jahnke, Spin labels as a tool to identify and characterize protein - ligand interactions by NMR spectroscopy, ChemBioChem 3(2002), 167-173.
187. R. V. C. Guido, M. S. Castilho, G. Oliva, A. D. Andricopulo, Structure-based pharmacophore strategies in drug design, Curr. Methods Med. Chem. Biol. Phys. 2(2008), 93-112.
188. K. M. Honorio, C. A. Montanari, A. D. Andricopulo, Advances and applications of structure-based approaches in drug discovery, Curr. Methods Med. Chem. Biol. Phys. 2(2008), 75-92.
189. A. M. Petros, S. W. Fesik, Nuclear magnetic resonance methods for studying protein-ligand complexes, Methods Enzymol. 239(1994), 717-739.
190. A. Medek, P. J. Hajduk, J. Mack, S. W. Fesik, The Use of Differential Chemical Shifts for Determining the Binding Site Location and Orientation of Protein-Bound Ligands, J. Am. Chem. Soc. 122(2000), 1241-1242.
191. M. Pellecchia, D. Meininger, Q. Dong, E. Chang, R. Jack, D. S. Sem, NMR-based structural characterization of large protein-ligand interactions, J. Biomol. NMR 22(2002), 165-173.
192. P. J. Hajduk, J. C. Mack, E. T. Olejniczak, C. Park, P. J. Dandliker, B. A. Beutel, SOS-NMR: A Saturation Transfer NMR-Based Method for Determining the Structures of Protein-Ligand Complexes, J. Am. Chem. Soc. 126(2004), 2390-2398.
193. D. S. Sem, L. Yu, S. M. Coutts, R. Jack, Object-oriented approach to drug design enabled by NMR SOLVE: first real-time structural tool for characterizing protein-ligand interactions, J. Cell. Biochem. (2001), 99-105.
194. M. A. McCoy D. F. Wyss, Alignment of weakly interacting molecules to protein surfaces using simulations of chemical shift perturbations, J. Biomol. NMR 18(2000), 189-198.
195. D. Sitkoff, D. A. Case, Theories of chemical shift anisotropies in proteins and nucleic acids, Prog. Nucl. Magn. Reson. Spectrosc. 32(1998), 165-190.
196. M. A. McCoy, D. F. Wyss, Spatial localization of ligand binding sites from electron current density surfaces calculated from NMR chemical shift perturbations, J. Am. Chem. Soc. 124(2002), 11758-11763.
197. K. Osapay, D. A. Case, A new analysis of proton chemical shifts in proteins, J. Am. Chem. Soc. 113(1991), 9436-9444.
198. A. Nicholls, K. A. Sharp, B. Honig, Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons, Proteins Struct. Funct. Genet. 11(1991), 281-296.
199. D. S. Goodsell, G. M. Morris, A. J. Olson, Automated docking of flexible ligands: applications of AutoDock, J. Mol. Recognit. 9(1996), 1-5.
200. M. R. McGann, H. R. Almond, A. Nicholls, J. A. Grant, F. K. Brown, Gaussian docking functions, Biopolymers 68(2003), 76-90.
201. D. T. Moustakas, P. T. Lang, S. Pegg, E. Pettersen, I. D. Kuntz, N. Brooijmans, R. C. Rizzo, Development and validation of a modular, extensible docking program: DOCK 5, J. Comput. Aided Mol. Des. 20(2006), 601-619.
202. G. B. McGaughey, R. P. Sheridan, C. I. Bayly, J. C. Culberson, C. Kreatsoulas, S. Lindsley, V. Maiorov, J. F. Truchon, W. D. Cornell, Comparison of topological, shape, and docking methods in virtual screening, J. Chem. Inf. Model 47(2007), 1504-1519.
203. M. A. McCoy, D. F. Wyss, Spatial localization of ligand binding sites from electron current density surfaces calculated from NMR chemical shift perturbations, J. Am. Chem. Soc. 124(2002), 11758-11763.
204. A. A. Lugovskoy, A. I. Degterev, A. F. Fahmy, P. Zhou, J. D. Gross, J. Yuan, G. Wagner, A Novel Approach for Characterizing Protein Ligand Complexes: Molecular Basis for Specificity of Small-Molecule Bcl-2 Inhibitors, J. Am. Chem. Soc. 124(2002), 1234-1240.
205. A. Fahmy, G. Wagner, TreeDock: A tool for protein docking based on minimizing van der Waals energies, J. Am. Chem. Soc. 124(2002), 1241-1250.
206. D. Gonzalez-Ruiz, H. Gohlke, Steering protein-ligand docking with quantitative NMR chemical shift perturbations, J. Chem. Inf. Model 49(2009), 2260-2271.
207. G. M. Morris, D. S. Goodsell, R. S. Halliday, R. Huey, W. E. Hart, R. K. Belew, A. J. Olson, Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function, J. Comput. Chem. 19(1998), 1639-1662.
208. M. D. Shortridge, R. Powers, Structural and Functional Similarity between the Bacterial Type III Secretion System Needle Protein PrgI and the Eukaryotic Apoptosis Bcl-2 Proteins, PLoS ONE 4(2009), 1-10.
209. C. Dominguez, R. Boelens, A. M. J. J. Bonvin, HADDOCK: A protein-protein docking approach based on biochemical or biophysical information, J. Am. Chem. Soc. 125(2003), 1731-1737.
210. M. Nilges, Ambiguous distance data in the calculation of NMR structures, Folding Des. 2(1997), S53-S57.
211. F. Sams-Dodd, Target-based drug discovery: is something wrong?, Drug Discov. Today 10(2005), 139-147.
212. J.-P. Garnier, Rebuilding the R&D engine in big pharma, Harv. Bus. Rev. 86(2008), 68-70, 72-6, 128.
213. J. A. Weisbach, W. H. Moos, Diagnosing the decline of major Pharm. Res. laboratories: a prescription for drug companies, Drug Dev. Res. 34(1995), 243-259.
214. D. F. Horrobin, Realism in drug discovery-could Cassandra be right?, Nat. Biotechnol. 19(2001), 1099-1100.
215. P. Cuatrecasas, Drug discovery in jeopardy, J. Clin. Invest. 116(2006), 2837-2842.
216. J. Owens, Big pharma slims down to bolster productivity, Nat. Rev. Drug Discovery 6(2007), 173-174.
217. C. G. Wermuth, Similarity in drugs: reflections on analogue design, Drug Discov. Today 11(2006), 348-354.
218. B. Booth, R. Zemmel, Opinion: Quest for the best, Nat. Rev. Drug Discovery 2(2003), 838-841.
219. D. Frishman, M. Mokrejs, D. Kosykh, G. Kastenmuller, G. Kolesov, I. Zubrzycki, C. Gruber, B. Geier, A. Kaps, K. Albermann, A. Volz, C. Wagner, M. Fellenberg, K. Heumann, H.-W. Mewes, The PEDANT genome database, Nucleic Acids Res. 31(2003), 207-211.
220. H. W. Mewes, D. Frishman, U. Gueldener, G. Mannhaupt, K. Mayer, M. Mokrejs, B. Morgenstern, M. Muensterkoetter, S. Rudd, B. Weil, MIPS: a database for genomes and protein sequences, Nucleic Acids Res. 30(2002), 31-34.
221. P. D. Thomas, A. Kejariwal, M. J. Campbell, H. Mi, K. Diemer, N. Guo, I. Ladunga, B. Ulitsky-Lazareva, A. Muruganujan, S. Rabkin, J. A. Vandergriff, O. Doremieux, PANTHER: A browsable database of gene products organized by biological function, using curated protein family and subfamily classification, Nucleic Acids Res. 31(2003), 334-341.
222. A. Bernal, U. Ear, N. Kyrpides, Genomes OnLine Database (GOLD): a monitor of genome projects world-wide, Nucleic Acids Res. 29(2001), 126-127.
223. M. T. Black, J. Hodgson, Novel target sites in bacteria for overcoming antibiotic resistance, Adv. Drug Delivery Rev. 57(2005), 1528-1538.
224. D. Lee, O. Redfern, C. Orengo, Predicting protein function from sequence and structure, Nat. Rev. Mol. Cell Biol. 8(2007), 995-1005.
225. A. Valencia, Automatic annotation of protein function. Curr. Opin. Struct. Biol. 15(2005), 267-274.
226. R. Rentzsch, C. A. Orengo, Protein function prediction-the power of multiplicity, Trends Biotechnol. 27(2009), 210-219.
227. J. A. Gerlt, P. C. Babbitt, Can sequence determine function?, GenomeBiology 1(2000), 1-10.
228. R. H. White, The difficult road from sequence to function, J. Bacteriol. 188(2006), 3431-3432.
229. S. L. Kinnings, R. M. Jackson, Binding site similarity analysis for the functional classification of the protein kinase family, J. Chem. Inf. Model 49(2009), 318-329.
230. R. J. Najmanovich, A. Allali-Hassani, R. J. Morris, L. Dombrovsky, P. W. Pan, M. Vedadi, A. N. Plotnikov, A. Edwards, C. Arrowsmith, J. M. Thornton, Analysis of binding site similarity, smallmolecule similarity and experimental binding profiles in the human cytosolic sulfotransferase family, Bioinformatics 23(2007), e104-109.
231. L. A. Mirny, E. I. Shakhnovich, Universally conserved positions in protein folds: reading evolutionary signals about stability, folding kinetics and function, J. Mol. Biol. 291(1999), 177-196.
232. R. Powers, J. C. Copeland, K. Germer, K. A. Mercier, V. Ramanathan, P. Revesz, Comparison of protein active site structures for functional annotation of proteins and drug design, Proteins 65(2006), 124-135.